In a Danish cohort study, individuals aged ≥70 years achieved a similar relative risk reduction of major vascular events with lipid-lowering therapy for primary prevention of CVD as those aged <70 years.

AHA 2023 In the SELECT trial, subcutaneous semaglutide 2.4 mg once weekly reduced the risk of CV events in patients with preexisting CVD and overweight or obesity who do not have diabetes.

AHA 2023 Apixaban reduced stroke or systemic embolism in patients with subclinical atrial fibrillation compared with aspirin in the ARTESIA trial. Apixaban increased the risk of major bleeding but there was no increase intracranial bleeding or fatal bleeding.

AHA 2023 In the absence of curative therapies for dementia, it was investigated whether a BP-lowering intervention can reduce the risk of dementia in patients with hypertension in China.

AHA 2023 In middle-aged individuals, a low-sodium diet significantly lowered SBP already within a week compared to the participants’ usual diet. The SBP reduction was independent of anti-hypertensive medication use and hypertension status.

AHA 2023 In the POP-HT trial, self-monitoring of BP in combination with physician guided anti-hypertensive medication adjustment during the first 6 weeks postpartum led to improvements in BP up to 9 months after a hypertensive pregnancy.

A population-based cohort study showed that cardio-renal-metabolic conditions (CVD, CKD, and T2D) and their overlap were increasingly common among US adults over the last 2 decades.

EASD 2023 In the SURMOUNT-4 trial, patients on 36-weeks of treatment with tirzepatide at maximally tolerated doses (10 mg or 15 mg) were randomized to continued therapy or discontinuation of therapy with placebo to assess whether body weight reductions by tirzepatide are maintained in people with obesity or overweight.

EASD 2023 A small randomized study showed that treatment with GLP-1RA semaglutide on top of empagliflozin did not have an additional beneficial effect on albuminuria in patients with T2D and albuminuria compared with placebo.

EASD 2023 In patients with T2D and HFmrEF/HFpEF, the treatment effect of dapagliflozin on the primary outcome was consistent across the number and most types of baseline glucose-lowering therapies.

ESC Congress 2023 In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

ESC Congress 2023 Stephen Nicholls shares the results of the total events analysis of the CLEAR Outcomes trial. He compares the hazard ratios of the first event and total events analyses and explains the implications of these results.